Journal for ImmunoTherapy of Cancer (Nov 2021)

312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%

  • Mark Awad,
  • Giuseppe Lamberti,
  • Lynette Sholl,
  • Joao Victor Alessi,
  • Stephanie Alden,
  • Victor Vaz,
  • Adriana Barrichello

DOI
https://doi.org/10.1136/jitc-2021-SITC2021.312
Journal volume & issue
Vol. 9, no. Suppl 2

Abstract

Read online

No abstracts available.